SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2020 / Cilt: 58 - Sayı: 2

Inflammation, Left Ventricular Mass Index and Chronic Renal Failure in Diabetic Patients

Diyabetik Hastalarda Enflamasyon, Sol Ventrikül Kitle İndeksi ve Kronik Böbrek Yetmezliği

Meltem GÜRSU
Savaş ÖZTÜRK
Egemen CEBECİ
Nilay Şengül SAMANCI
Sami UZUN
Serhat KARADAĞ
Tuba Elif ŞENEL ÖZLER
Mustafa VELET
Pages
129–134
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with an estimated glomerular filtrationrate (eGFR) of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to determine the relationshipbetween left ventricular hypertrophy (LVH) and inflammatorymarkers in patients with type 2 Diabetes Mellitus (T2DM) withdiabetic nephropathy at different stages.Methods: Our study was a cross-sectional study involvingpatients with various stage of T2DM.
📊
Key Findings & Data:Patients with LVH wereidentified by 2D echocardiography.
💡
Conclusion & Impact:Patients with an estimated glomerular filtrationrate (eGFR) of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study was to determine the relationshipbetween left ventricular hypertrophy (LVH) and inflammatorymarkers in patients with type 2 Diabetes Mellitus (T2DM) withdiabetic nephropathy at different stages.Methods: Our study was a cross-sectional study involvingpatients with various stage of T2DM. Patients with LVH wereidentified by 2D echocardiography. Plasma human tumor necrosisfactor alpha (TNF-α), interleukin (IL)-1, IL-6, vaspin, vispatin andmidkine were measured.Results: A total of 59 T2DM patients (56% women) with a meanage of 56.1±8.8 years were included in the study. The mean leftventricular mass index was 129±30. LVH was detected in 62.7%of the patients. Patients with an estimated glomerular filtrationrate (eGFR) of

Özet

Amaç: Çalışmamızın amacı farklı evrelerdeki tip 2 Diabetes Mellitus (T2DM) hastalarında sol ventrikül hipertrofisi (SVH) ve enflamatuvar biyobelirteçlerin arasındaki ilişkiyi ortaya koymaktır. Yöntemler: Kesitsel çalışmamıza çeşitli evrelerdeki T2DM hastaları dahil edildi. SVH 2D ekokardiyografi cihazı ile değerlendirildi. Tümor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-6, vaspin, vispatin ve midkine serumda ölçüldü. Bulgular: Ortalama yaşı 56,1±8,8 yıl olan 59 T2DM hastası (%56’sı kadın) çalışmaya dahil edildi. Sol ventrikül kitle indeksi 129±30 idi. SVH’si hastaların %62,7’sinde saptandı. Tahmini glomerüler filtrasyon hızı (tGFH)

🔖

Cite This Article

GÜRSU, M., ÖZTÜRK, S., CEBECİ, E., SAMANCI, N. Ş., UZUN, S., KARADAĞ, S., ÖZLER, T. E. Ş., VELET, M. (2022). Inflammation, Left Ventricular Mass Index and Chronic Renal Failure in Diabetic Patients. Haseki Tıp Bülteni, Cilt: 58 - Sayı: 2, 129–134. https://ajindex.com/articles/535019

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
  2. De Jong KA, Czeczor JK, Sithara S, et al. Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study. Cardiovasc Diabetol 2017;16:21
  3. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 1989;36:286-90
  4. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Failure Reviews 2014;19:681-94
  5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35 Suppl 1:S64-S71
  6. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8
  7. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-HEART). Circulation 1998;98:1510-6
  8. Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic andclinical perspectives. Trends Cardiovasc Med 2007;17:275-83
  9. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissuederived serine protease inhibitor: Aunique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci Unit States Am 2005;102:10610-5
  10. Horiba M, Kadomatsu K, Yasui K, et al. Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction. Circulation 2006;114:1713-20
  11. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30
  12. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58
  13. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of Visfatin in macrophages of human unstable carotid and coronary atherosclerosis possible role in inflammation and plaque destabilization. Circulation 2007;115:972-80
  14. Nishimura M, Hashimoto T, Kobayashi H, et al. Association betwee